《新英格兰医学杂志》发布三期临床研究Ascent-04/Keynote-D19结果：Trodelvy®联合Keytruda®有望成为PD-L1阳性转移性三阴性乳腺癌一线治疗新标准

美股速递01-22

《新英格兰医学杂志》最新刊发的三期临床试验Ascent-04/Keynote-D19研究数据显示，Trodelvy®与Keytruda®联合疗法展现出显著疗效。这一突破性进展为PD-L1阳性转移性三阴性乳腺癌患者的一线治疗提供了新选择。

研究结果证实，联合用药方案在客观缓解率和无进展生存期等关键指标上均优于现有标准疗法。该疗法有望重塑临床实践格局，为晚期三阴性乳腺癌治疗领域注入新动能。

此次发布的数据进一步验证了免疫联合靶向治疗的协同作用机制。随着后续研究推进，这种创新组合或将成为该类患者群体的一线标准治疗方案。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1175285034?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-22 06:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175285034","market":"us","top_or_hot":-1,"title":"《新英格兰医学杂志》发布三期临床研究Ascent-04/Keynote-D19结果：Trodelvy®联合Keytruda®有望成为PD-L1阳性转移性三阴性乳腺癌一线治疗新标准","media":"美股速递","content":"<p>《新英格兰医学杂志》最新刊发的三期临床试验Ascent-04/Keynote-D19研究数据显示，Trodelvy®与Keytruda®联合疗法展现出显著疗效。这一突破性进展为PD-L1阳性转移性三阴性乳腺癌患者的一线治疗提供了新选择。</p>\n<p>研究结果证实，联合用药方案在客观缓解率和无进展生存期等关键指标上均优于现有标准疗法。该疗法有望重塑临床实践格局，为晚期三阴性乳腺癌治疗领域注入新动能。</p>\n<p>此次发布的数据进一步验证了免疫联合靶向治疗的协同作用机制。随着后续研究推进，这种创新组合或将成为该类患者群体的一线标准治疗方案。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《新英格兰医学杂志》发布三期临床研究Ascent-04/Keynote-D19结果：Trodelvy®联合Keytruda®有望成为PD-L1阳性转移性三阴性乳腺癌一线治疗新标准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《新英格兰医学杂志》发布三期临床研究Ascent-04/Keynote-D19结果：Trodelvy®联合Keytruda®有望成为PD-L1阳性转移性三阴性乳腺癌一线治疗新标准\n</h2>\n\n<h4 class=\"meta\">\n\n2026-01-22 06:02 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>《新英格兰医学杂志》最新刊发的三期临床试验Ascent-04/Keynote-D19研究数据显示，Trodelvy®与Keytruda®联合疗法展现出显著疗效。这一突破性进展为PD-L1阳性转移性三阴性乳腺癌患者的一线治疗提供了新选择。\n研究结果证实，联合用药方案在客观缓解率和无进展生存期等关键指标上均优于现有标准疗法。该疗法有望重塑临床实践格局，为晚期三阴性乳腺癌治疗领域注入新动能。\n此次发布的...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1778281490.HKD","symbol_name":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","start_time":0,"source_url":"","article_id":"1175285034","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175285034","pubTimestamp":1769032941,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"《新英格兰医学杂志》最新刊发的三期临床试验Ascent-04/Keynote-D19研究数据显示，Trodelvy®与Keytruda®联合疗法展现出显著疗效。这一突破性进展为PD-L1阳性转移性三阴性乳腺癌患者的一线治疗提供了新选择。\n研究结果证实，联合用药方案在客观缓解率和无进展生存期等关键指标上均优于现有标准疗法。该疗法有望重塑临床实践格局，为晚期三阴性乳腺癌治疗领域注入新动能。\n此次发布的数据进一步验证了免疫联合靶向治疗的协同作用机制。随着后续研究推进，这种创新组合或将成为该类患者群体的一线标准治疗方案。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","LU0058720904.USD":"联博国际健康护理基金A","BK4532":"文艺复兴科技持仓","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4585":"ETF&股票定投概念","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4139":"生物科技","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","BK4566":"资本集团","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4578":"CAR-T","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","BK4588":"碎股","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","SG9999015978.USD":"利安颠覆性创新基金A","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","GILD":"吉利德科学","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4583":"猴痘概念"},"translate_title":"\"New England Journal of Medicine\" releases results of phase III clinical study Ascent-04/Keynote-D19: Trodelvy ® Joint Keytruda ® It is expected to become a new standard for first-line treatment of PD-L1-positive metastatic triple-negative breast cancer","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":1},"content_text":"《新英格兰医学杂志》最新刊发的三期临床试验Ascent-04/Keynote-D19研究数据显示，Trodelvy®与Keytruda®联合疗法展现出显著疗效。这一突破性进展为PD-L1阳性转移性三阴性乳腺癌患者的一线治疗提供了新选择。\n研究结果证实，联合用药方案在客观缓解率和无进展生存期等关键指标上均优于现有标准疗法。该疗法有望重塑临床实践格局，为晚期三阴性乳腺癌治疗领域注入新动能。\n此次发布的数据进一步验证了免疫联合靶向治疗的协同作用机制。随着后续研究推进，这种创新组合或将成为该类患者群体的一线标准治疗方案。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175285034","isCrawlerRequest":true}